Fecal Analysis in the Diagnosis of Intestinal Dysbiosis and Fecal Microbiota Transplant Testing
Defines BCBSNM reimbursement rules for laboratory testing of donor fecal samples for FMT and for fecal analysis used to evaluate intestinal dysbiosis and related conditions; applies to providers submitting claims to Blue Cross Blue Shield of New Mexico.
Edited reimbursement items #1, #2, #3 to clarify that fecal microbiota transplantation testing is on the sample coming from the donor.
Item #4.h (list of organisms/tests) was edited for clarity.
Added procedure codes 87076, 87077, 87081, 87106 to the policy code list.
Removed multiple previously listed codes including 82239, 82725, 82784, 83520, 83630, 87177, 87209, 87328, 87329, 87336.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.